Advaxis, Inc., (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced business highlights and financial results for the fiscal year 2018 third quarter, ended July 31, 2018.
September 10, 2018
· 8 min read